Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $640,278.90 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Lauren Duprey sold 34,535 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $18.54, for a total transaction of $640,278.90. Following the transaction, the insider owned 191,522 shares in the company, valued at $3,550,817.88. The trade was a 15.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Lauren Rusckowski Duprey also recently made the following trade(s):

• On Monday, August 10th, Lauren Duprey sold 47,586 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $17.10, for a total transaction of $813,720.60.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock opened at $19.06 on Friday. Takeda Pharmaceutical Co. has a 52-week low of $12.99 and a 52-week high of $19.10. The stock has a market capitalization of $61.07 billion, a price-to-earnings ratio of 56.06 and a beta of -0.07. The company has a fifty day moving average of $17.67 and a 200-day moving average of $17.19. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, July 30th. The company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.54. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The company had revenue of $7.50 billion for the quarter, compared to analysts’ expectations of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Equities research analysts expect that Takeda Pharmaceutical Co. will post 1.54 EPS for the current year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Several hedge funds and other institutional investors have recently modified their holdings of TAK. Capital Research Global Investors increased its stake in shares of Takeda Pharmaceutical by 0.6% during the fourth quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock valued at $210,259,000 after buying an additional 82,643 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in Takeda Pharmaceutical by 100.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock valued at $88,596,000 after acquiring an additional 2,854,069 shares in the last quarter. Renaissance Technologies LLC increased its position in Takeda Pharmaceutical by 14.2% during the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock valued at $55,358,000 after purchasing an additional 370,800 shares during the period. Quantinno Capital Management LP increased its position in Takeda Pharmaceutical by 20.6% during the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after purchasing an additional 219,999 shares during the period. Finally, Royal Bank of Canada raised its holdings in Takeda Pharmaceutical by 11.0% in the 1st quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock worth $11,386,000 after purchasing an additional 60,725 shares in the last quarter. 9.17% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on TAK. Zacks Research raised Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 2nd. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings upgraded Takeda Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, September 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Buy”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Japan. The company researches, develops, manufactures and markets prescription medicines and vaccines for patients and healthcare professionals around the world.

Takeda focuses on several therapeutic areas, including gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, Ninlaro for multiple myeloma and Iclusig for certain blood cancers, along with other specialty medicines and vaccines.

Founded in Osaka in 1781, Takeda has grown from a traditional pharmaceutical distributor into an international biopharmaceutical company serving markets across Japan, North America, Europe and other regions.